Obeticholic Acid

ʻO ka wehewehe pōkole:

Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
Obeticholic Acid Biliary cholangitis I-Hale      


Huahana Huahana

Huahana Huahana

NUI HUA

wehewehe

ʻO kaʻakika Obeticholic (INT-747) he mea ikaika, koho a hoʻoikaika waha FXR agonist me kahi EC50 o 99 nM.He anticholeretic a me ka hopena anti-inflammation ka Obeticholic acid.Hoʻokomo pū ka Obeticholic acid i ka autophagy [1][2][3].

 

Ka hope

ʻO ka Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECDCA, INT-747) he agonist ikaika a koho i ka FXR me ka waiwai EC50 o 99 nM [1].

ʻO ka farnesoid X receptor (FXR) he nuklear bile acid receptor e pili ana i ka homeostasis acid bile, fibrosis ate, hepatic and intestinal inflammation a me ka maʻi cardiovascular [2].

ʻO ka Obeticholic Acid kahi agonist FXR ikaika a koho me ka hana anticholeretic [1].ʻO ka Obeticholic Acid he semisynthetic bile acid derivative a me ka ikaika FXR ligand.I loko o ka estrogen-induced cholestasis iole, 6-ECDCA pale aku i ka cholestasis i hookomoia e 17α-ethynylestradiol (E217α) [2].Ma nā ʻano ʻiole cirrhotic portal hypertension (PHT), ua hoʻāla hou ʻo INT-747 (30 mg/kg) i ke ala hōʻailona FXR downstream a hoʻemi i ke kaomi puka ma ka hoʻohaʻahaʻa ʻana i ka nui intrahepatic vascular resistance (IHVR) me ka ʻole o ka hypotension systemic deleterious.Ua pili kēia hopena me ka hoʻonui ʻana i ka hana eNOS [3].I ka Dahl rat model of salt-sensitive hypertension a me insulin-resistance (IR), kiʻekiʻe paʻakai (HS) meaʻai nui hoʻonui systemic koko a me downregulated kiko DDAH hōʻike.Hoʻonui ka INT-747 i ka naʻau o ka insulin a kāohi i ka emi ʻana o ka ʻōlelo DDAH [4].

Kuhikuhi:
[1].Pellicciari R, Fiorucci S, Camaioni E, et al.ʻO ka 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), kahi agonist FXR ikaika a koho i hāʻawi ʻia me ka hana anticholestatic.J Med Chem, 2002, 45(17): 3569-3572.
[2].Fiorucci S, Clerici C, Antonelli E, et al.Nā hopena pale o ka 6-ethyl chenodeoxycholic acid, he farnesoid X receptor ligand, i loko o ka estrogen-induced cholestasis.J Pharmacol Exp Ther, 2005, 313(2): 604-612.
[3].Verbeke L, Farre R, Trebicka J, a me al.Obeticholic acid, he farnesoid X receptor agonist, hoʻomaikaʻi i ke kiʻekiʻe kiʻekiʻe o ka puka ma nā ala ʻelua i nā ʻiole cirrhotic.Hepatology, 2014, 59 (6): 2286-2298.
[4].Ghebremariam YT, Yamada K, Lee JC, et al.Hoʻonui ka FXR agonist INT-747 i ka hōʻike DDAH a hoʻonui i ka ʻike insulin i nā ʻiole Dahl hānai kiʻekiʻe.PLoS One, 2013, 8(4): e60653.

Huahana Huahana

  • 1. Selina Costa."Ka hōʻike ʻana i kahi Novel Ligand no ka Farnesoid X Receptor me ka hoʻohana ʻana i Transgenic Zebrafish."Kulanui o Toronto.Iune-2018.
  • 2. Kent, Rebeka."Nā hopena o Fenofibrate ma CYP2D6 a me ka hoʻoponopono o ANG1 a me RNASE4 e ka FXR Agonist Obeticholic Acid."indigo.uic.edu.2017.

 

Waihona

Pauda

-20°C

3 makahiki
 

4°C

2 makahiki
I ka solvent

-80°C

6 mahina
 

-20°C

1 mahina

ʻO ke kinona

Obeticholic Acid

ʻIkepili olaola pili

Obeticholic Acid2

ʻIkepili olaola pili

Obeticholic Acid3

HOOLAHA ANOAI

Quality management1

Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.

Quality management2

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Quality management3

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Quality management4

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.

HOOLAHA HANA

cpf5
cpf6

Kolea Countec Bottled Packaging Line

cpf7
cpf8

ʻO Taiwan CVC Bottled Packaging Line

cpf9
cpf10

ʻO Italia CAM Board Packaging Line

cpf11

Mekini Fette Compacting German

cpf12

ʻO Iapana Viswill Tablet ʻIke

cpf14-1

Keena Mana DCS

HOA

Ka launa pū ʻana o ka honua
International cooperation
ʻO ka launa pū ʻana o ka hale
Domestic cooperation

  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou

    Māhele huahana